Vedotin refers to a class of antibody-drug conjugates (ADCs) that pair a monoclonal antibody with the potent, synthetic cytotoxic agent Monomethyl Auristatin E (MMAE) via a protease-cleavable linker. These targeted therapies, including Brentuximab vedotin (Adcetris) and Tisotumab vedotin (Tivdak), kill cancer cells by inhibiting microtubule assembly, leading to cell cycle arrest and apoptosis. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Vedotin radical and Monomethyl auristatin E. It is also listed for alternate use as: API Intermediate. Its PubChem CID is 53297465.
Vedotin
| CAS No | 646502-53-6 |
|---|---|
| Molecular Formula | C39H67N5O7 |
| Molecular Weight | 718.0 g/mol |
| Synonyms | (2S)-N-[(2S)-1-[[(3R,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Vedotin refers to a class of antibody-drug conjugates (ADCs) that pair a monoclonal antibody with the potent, synthetic cytotoxic agent Monomethyl Auristatin E (MMAE) via a protease-cleavable linker.
The listed CAS number is 646502-53-6.
The listed molecular formula is C39H67N5O7.
The listed molecular weight is 718.0 g/mol.
(2S)-N-[(2S)-1-[[(3R,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide.
The source lists Vedotin radical and Monomethyl auristatin E.